NKT2152

NKT2152 (NiKang Therapeutics): sourced facts only. name: "Here, we report the discovery of NKT2152 (Imdatifan), a potent, selective, and orally available small molecule HIF-2α inhibitor identified through rational design." [PMID:42445002]; target: "Here, we report the discovery of NKT2152 (Imdatifan), a potent, selective, and orally available small molecule HIF-2α inhibitor identified through rational design." [PMID:42445002]; developer: "NiKang Therapeutics Inc., 200 Powder Mill Rd., Bldg E500, Wilmington, Delaware 19803, United States." [PMID:42445002]; modality: "Here, we report the discovery of NKT2152 (Imdatifan), a potent, selective, and orally available small molecule HIF-2α inhibitor identified through rational design." [PMID:42445002]; stage: "NKT2152 disrupts the HIF-2α/HIF-1β complex, selectively suppressing target gene expression in VHL-deficient 786-O ccRCC cells." [PMID:42445002]